Rhenman & Partners Asset Management Ab Coherus Bio Sciences, Inc. Transaction History

Rhenman & Partners Asset Management Ab

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 17, 2020	SELL	$16.33 - $21.37 $4.74 Million - $6.2 Million	-290,000 Closed	0 $0
Q3 2019 Oct 16, 2019	SELL	$16.3 - $23.37 $1.63 Million - $2.34 Million	-100,000 Reduced 25.64%	290,000 $5.88 Million
Q2 2019 Jul 22, 2019	SELL	$13.1 - $22.1 $800,816 - $1.35 Million	-61,131 Reduced 13.55%	390,000 $8.62 Million
Q1 2019 Apr 11, 2019	BUY	$8.38 - $15.5 $1.09 Million - $2.02 Million	130,000 Added 40.48%	451,131 $6.15 Million
Q4 2018 Feb 05, 2019	SELL	$8.65 - $16.28 $86,500 - $162,800	-10,000 Reduced 3.02%	321,131 $2.91 Million
Q3 2018 Oct 03, 2018	SELL	$14.45 - $20.25 $272,657 - $382,097	-18,869 Reduced 5.39%	331,131 $5.46 Million
Q4 2017 Jan 19, 2018	BUY	$8.35 - $14.4 $1.42 Million - $2.45 Million	170,000 Added 94.44%	350,000 $3.08 Million
Q3 2017 Oct 13, 2017	BUY	$11.1 - $14.5 $2 Million - $2.61 Million	180,000	180,000 $2.4 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $132M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.